title: Impact of various tumor markers in prognosis of gastric cancer. A hospital based study from tertiary care hospital of Kathmandu valley.
abstract: BACKGROUND
  To obtain the maximum additional information about the prognosis of gastric cancer, we compared CA-50 with other previously defined markers.
  
  
  METHODS
  This hospital based study was carried out in the Department of Biochemistry of Nepalese Army Institute of Health Sciences between 1st July 2012 and 31st December 2012. The variables collected were age, gender, AFP, CEA, CA19-9, and CA50, assayed with ELISA reader for all cases. The cut off values for serum AFP, CEA, CA19-9, and CA-50 were 10 μg/l, 10 μg/l, 37 U/ml, and 20 U/ml, respectively according to the manufacturer's instructions. Approval for the study was obtained from the institutional research ethical committee.
  
  
  RESULTS
  Of the 40 examined patients, 13 patients had tumors located in the upper third of the stomach, 6 patients had tumors in the middle third, 16 patients had tumors in the lower third, and 5 patients had tumors occupying two-thirds of the stomach or more. The distribution of lymph node staging of the patients was as follows: 7 patients belonged to N0, 9 patients to N1 stage, 10 patients to N2 stage, and 14 patients to N3 stage. The statistical method of Cox proportional hazards using multivariate analysis also illustrated that tumor markers including CEA (2.802), CA19-9 (2.690), CA50 (2.101), were independent prognostic factors, as tumor size (1.603), and lymph node stage (1.614).
  
  
  CONCLUSIONS
  The tumour markers now available, like CEA, CA 19-9 and CA 50, chiefly perceive advanced gastric cancer. The preoperative rise in those tumour marker level have a prognostic significance and may be clinically helpful in choosing patients for adjuvant management.
authors.affiliation: Department of Biochemistry, Nepalese Army Institute of Health Sciences, Kathmandu, Nepal. drmittala@gmail.com
authors.forename: Ankush
authors.initials: A
authors.lastname: Mittal
authors.forename: Satrudhan Pd
authors.initials: SP
authors.lastname: Gupta
authors.forename: Dipendra Kumar
authors.initials: DK
authors.lastname: Jha
authors.forename: Brijesh
authors.initials: B
authors.lastname: Sathian
authors.forename: Bibek
authors.initials: B
authors.lastname: Poudel
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000401:mortality* / Q000628:therapy; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D013274:Stomach Neoplasms / Q000097:blood / Q000401:mortality* / Q000628:therapy; D015996:Survival Rate; D062606:Tertiary Care Centers
chemical_list: D014408:Biomarkers, Tumor